Concerns About the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure 8 Blood Pressure Panel Member Recommendations and Their Relevance to Metabolic Syndrome
Restricted accessArticle commentaryFirst published online June, 2014
Concerns About the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure 8 Blood Pressure Panel Member Recommendations and Their Relevance to Metabolic Syndrome
NwankwoT, YoonSS, BurtV, GuQ. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief, 2013Oct(133):1–8.
2.
Center for Disease Control and prevention. NHANES Response Rates and Population Totals. Distribution of the Civilian Noninstitutionalized U.S. Population for Use with the NHANES 2011–2012 Survey Cycle: by Gender, Age, and Race/Hispanic Origin. Atlanta, GA: Centers for Disease Control and Prevention. 2013. Available at www.cdc.gov/nchs/nhanes/response_rates_CP.htm Accessed March9, 2014.
3.
MenkesMS, MatthewsKA, KrantzDS, et al.Cardiovascular reactivity to the cold pressure test as a predictor of hypertension. Hypertension, 1989; 14:524–530.
4.
FalknerB, OnestiG, AngelakosET, FernandesM, LangmarC. Cardiovascular response to mental stress in normal adolescents with hypertensive parents. Hypertension, 1979; 1:23–30.
5.
FredriksonM. Psychophysiological theories on sympathetic nervous reactivity in the development of essential hypertension. Scand J Psychol, 1991; 32:254–274.
6.
MatthewsCE, PateRR, JacksonKL, et al.Exaggerated blood pressure response to dynamic exercise and risk of future hypertension. J Clin Epidemiol, 1998; 51:29–35.
7.
ChaneyRH, EymanRK. Blood pressure at rest and maximal dynamic and isometric exercise as predictors of systemic hypertension. Am J Cardiol, 1988; 62:1058–1061.
8.
ChobanianAV, BakrisGL, BlackHR, et al.Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003; 42:1206–1252.
9.
JamesPA, OparilS, CarterBL, et al.2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 2014; 311:507–520.
10.
GibbonsGH, ShurinSB, MensahGA, et al.Refocusing the agenda on cardiovascular guidelines: An announcement from the National Heart, Lung, and Blood Institute. J Am Coll Cardiol, 2013, 8; 62:1396–1398.
11.
WrightJT, FineLJ, LacklandDT, et al.Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients 60 years or older: The minority view. Ann Intern Med PMID: 24424788.
12.
SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991; 265:3255–3264.
13.
BeckettNS, PetersR, FletcherAE, et al.HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med, 2008; 358:1887–1898
14.
ReboldiG, AngeliF, de SimoneG, et al.; Cardio-Sis Investigators. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension, 2014; 63:475–482.
15.
ManciaG, FagardR, NarkiewiczK, et al.2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press, 2014; 23:3–16.
16.
HackamDG, QuinnRR, RavaniP, et al.Canadian Hypertension Education Program. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol, 2013; 29:528–542.
17.
National Institutes for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. Clinical guidelines, methods, evidence and recommendations. London: National Institutes for Health and Clinical Excellence, 2011.
18.
AronowWS, FlegJL, PepineCJ, et al.ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol, 2011; 57:2037–2114.
19.
WeberMA, SchiffrinEL, WhiteWB, et al.Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich), 2014; 16:14–26.
20.
EckelRH, GrundySM, ZimmetPZ. The metabolic syndrome. Lancet, 2005; 365:1415–1428.
21.
IsomaaB, AlmgrenP, TuomiT, et al.Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001; 24:683–689.
22.
GrundySM, CleemanJI, DanielsSR, et al.Diagnosis and management of the metabolic syndrome: An Amrican Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112:2735–2752.
23.
EckelRH, KahnR, RobertsRM, et al.Preventing cardiovascular disease and diabetes. A call to action from ADA and AHA. Circulation, 2006; 113:2943–2946.
24.
GamiAS, WittBJ, HowardDE, et al.Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 2007; 30; 49:403–414.
25.
FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287:356–359.
26.
SiegelD, SwislockiA. Treatment of hypertension in patients with the metabolic syndrome. Met Syndr Relat Disord, 2010; 8:95–104.
27.
SavagePJ, PresselSL, CurbJD, et al.Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med, 1998; 158:741–751.
28.
SiegelD, MeierJ, MaasC, LopezJ, SwislockiALM, The effect of body mass index on fasting blood glucose after initiation of thiazide therapy in hypertensive patients. Am J Hypertens, 2008; 21:438–442.
29.
LithellH, PollareT, VessbyB. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press, 1992; 1:92–101.
30.
GressTW, NietoFJ, ShaharE, WoofordMR, BrancatiFL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. N Engl J Med, 2000; 342:905–912.
31.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J, 1998; 317:713–720.
32.
BakrisGL, FonsecaV, AtholiRE, et al.Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension, a randomized controlled trial. JAMA, 2004; 292:2227–2236.
33.
Jandeleit-DahmKA, TikelisC, ReidCM, et al.Why blockage of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens, 2005; 23:463–473.
34.
HanssonL, LindholmLH, NiskanenL, et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet, 1999; 353:611–616.
35.
DahlöfB, DevereuxRB, KjeldsenSE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet, 2002; 359:995–1003.
36.
SheuWH, SwislockiAL, HoffmanB, ChenYD, ReavenGM. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens, 1991; 4:199–205.
37.
NathanS, PepineCJ, BakrisGL. Calcium antagonists: Effects on cardio-renal risk in hypertensive patients. Hypertension, 2005; 46:637–642.
38.
SwislockiAL, HoffmanBB, SheuWH, et al.Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med, 1989; 86:14–18.
39.
PessinaAC, CiccarielloL, PerroneF, et al.Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis, 2006; 16:137–147.
